Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium
Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…Abstract Number: 44 • 2019 ACR/ARP Annual Meeting
Validation of New Genes Identified in a Molecular Bayesian Network of Rheumatoid Arthritis Synovitis
Background/Purpose: We have previously identified new key regulators of Rheumatoid arthritis (RA) synovial pathology using a systems biology approach that combined RA gene expression datasets,…Abstract Number: 1195 • 2019 ACR/ARP Annual Meeting
Quantitative Physician Global Assessment of Damage And/or Distress, in Addition to Inflammation, at Routine Rheumatology Care: Documenting the Complexity of Rheumatology Patient Encounters as a Rationale for Possible Higher Reimbursement?
Background/Purpose: Quantitative clinical measures and indices such as DAS28, CDAI, SLEDAI, BASDAI, are designed to assess inflammation, reflecting a goal to prevent long-term damage, and…Abstract Number: 1814 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era
Background/Purpose: After nearly two decades from the start of the Biologic era, systematic analyses of patients with juvenile idiopathic arthritis (JIA) have shown a high…Abstract Number: 51 • 2018 ACR/ARHP Annual Meeting
Genetic Ablation of Inducible Nitric Oxide Synthase in TNF Transgenic Mice with Inflammatory-Erosive Arthritis Prevents Lymph Node Expansion and Decreases Synovial Infiltrates
Background/Purpose: Recent studies in the TNF-Tg mouse model of rheumatoid arthritis (RA) demonstrated a critical role of lymphatic vessel (LV) function in joint homeostasis and…Abstract Number: 1198 • 2018 ACR/ARHP Annual Meeting
Ultrasound-Detected Joint Erosions in Rheumatoid Arthritis: What Every Sonographer Should Know
Background/Purpose: Previous work in rheumatoid arthritis (RA) on bone erosion(s) using ultrasound (US) focused mostly on small joints of the fingers and toes. We aim…Abstract Number: 1447 • 2018 ACR/ARHP Annual Meeting
Decreased Lymphatic Drainage in the Hands of Flaring RA Patients As Measured By Indocyanine Green Clearance Via Real Time Near Infrared Imaging
Background/Purpose: Near infrared (NIR) imaging studies of subdermal indocyanine green (ICG) in murine models of inflammatory arthritis established abnormal lymphatic vessel (LV) function during arthritic…Abstract Number: 1450 • 2018 ACR/ARHP Annual Meeting
Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy
Background/Purpose: Rheumatologists rely on hand radiograph findings including bone erosions (BE) and joint space narrowing (JSN) to make treatment decisions for patients with rheumatoid arthritis…Abstract Number: 1998 • 2018 ACR/ARHP Annual Meeting
Autophagy-Related Molecules Detected in Blood and Cartilage Are Biomarkers of Joint Damage in OA
Background/Purpose: In osteoarthritis (OA), defects in cellular homeostasis, and in particular in autophagy, are evident and precede joint damage. We have shown that there is…Abstract Number: 2515 • 2018 ACR/ARHP Annual Meeting
Joint Damage Progression According to Disease Activity States in Patients with Rheumatoid Arthritis Treated with CT-P10 and Reference Rituximab: Up to 48 Weeks Results from Phase III Study
Background/Purpose: CT-P10 is a biosimilar of the reference rituximab (RTX) and has been approved by several regulatory agencies including EMA. Pharmacokinetic and therapeutic equivalence from…Abstract Number: 533 • 2017 ACR/ARHP Annual Meeting
Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The long-term safety and clinical efficacy of tofacitinib 5 and 10 mg…Abstract Number: 1101 • 2017 ACR/ARHP Annual Meeting
Systematic Physician Assessment Beyond Inflammation in Routine Rheumatology Care Using Visual Analog Scale Scores for Inflammation, Damage, and Distress to Document Patient Status and Support Clinical Decisions: Analysis of Inter-Rater Reliability
Background/Purpose: A physician global estimate of patient status (DOCGL) on a 0-10 visual analog scales (VAS) is as effective as any rheumatoid arthritis (RA) Core…Abstract Number: 1366 • 2017 ACR/ARHP Annual Meeting
Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in severe joint damage and physical disability, therefore, the discovery of new marker(s) for…Abstract Number: 2245 • 2017 ACR/ARHP Annual Meeting
The Effects of Structural Damage on Functional Disability in Psoriatic Arthritis
Background/Purpose: Functional outcomes are central in patients with chronic inflammatory musculoskeletal diseases. In a secondary data analysis of the GO-REVEAL trial we investigated if structural…
- 1
- 2
- 3
- 4
- Next Page »